Botulinum Toxin Type A Reconstituited with Lidocaine: A Report of 356 Consecutive Cases
DOI:
https://doi.org/10.31907/2414-2093.2015.01.1Keywords:
Botulinum toxin, Facial aesthetic, Minimally-invasive, Lidocaine.Abstract
Background: The purpose of this paper is to evaluate the predictability of the off-label aesthetic use of botulinum toxin type A (BoNTA) reconstituted with lidocaine.
Material and Methods: Three-hundred and fifty-six (356) BoNTA treatments were performed on 118 patients, between the January 2010 and the January 2013; BoNTA was reconstituited with lidocaine.
Results: A few minute after the BoNTA injection the effect of muscle paralysis was seen in all the cases, this allowed the Author to provide an optimal symmetric result with no need of a touch up procedure at the control after a week. Maior complication were not registered.
Conclusion: The results of this study shows how the reconstitution of BoNTA with lidocaine may avoid imperfect results after the injections; all components retain their function and immediate feedback on the extent of paralysis to be expected from the chemodenervation action of BoNTA let the physician to have an immediate control of the final result.
References
Tremaine AM, McCullogh JL. Botulinum toxin type A for the management of glabellar rhytids. Clin Cosmet Invest Dermatol. 2010; 3: 15-23. http://dx.doi.org/10.2147/CCID.S6492
National Institutes of Health (NIH). Clinical use of botulinumtoxin. National Institutes of Health Consensus Development Conference Statement, November 12Y14, 1990. Arch Neurol 1991; 48: 1294. http://dx.doi.org/10.1001/archneur.1991.00530240100030
Jost WH. Other indications of Botulinum toxin therapy. Eur J Neur 2006; 13: 65Y69.
Tartaro G, Rauso R, Santagata M, Santillo V, Itro A. Lower facial contouring with botulinum toxin type A. J Craniofac Surg 2008; 19(6): 1613-7. http://dx.doi.org/10.1097/SCS.0b013e31818973c8
Stephan S, Wang TD. Botulinum toxin: Clinical techniques, applications, and complications. Facial Plast Surg 2011; 27: 529-539. http://dx.doi.org/10.1055/s-0031-1298786
De Maio M, Rzany B. Botulinum toxin in aesthetic medicine. Springer-Verlag Berlin Heidelberg 2007.
Carruthers JD, Carruthers JA. Treatment of glabellar frown lines with C. botulinum-A exotoxin. J Dermatol Surg Oncol 1992; 18(1): 17-21. http://dx.doi.org/10.1111/j.1524-4725.1992.tb03295.x
Wise JB, Greco T. Injectable treatments for the aging face. Facial Plast Surg 2006; 22: 140-146. http://dx.doi.org/10.1055/s-2006-947720
Vadoud-Seyedi J, Simonart T. Treatment of axillary hyperhidrosis with boulinum toxin type A reconstituited in lidocaine or in normal saline solution: a randomized, side by side, double blind study. Br J Dermatol. 2007; 156(5): 986-9. http://dx.doi.org/10.1111/j.1365-2133.2007.07760.x
Gulec AT. Diluition of botulinum toxin A in lidocaine vs. in normal saline for the treatment of primary axillary hyperidrosis: a double-blinded, randomized, comparative preliminary study. J Eur Acad Dermatol Venereol. 2012; 26(3): 314-8. http://dx.doi.org/10.1111/j.1468-3083.2011.04066.x
Gassner HG, Sherris DA. Addition of anesthetic agent to enhance the predictability of the effects of botulinum toxin type A injections: a randomized controlled study. Mayo Clin Proc 2000; 75(7): 701-4. http://dx.doi.org/10.1016/S0025-6196(11)64616-8
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
